hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06345183 id: CA209-1275 briefTitle: Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients overallStatus: RECRUITING date: 2024-02-19 date: 2024-04-01 date: 2024-12-31 date: 2024-04-03 date: 2024-04-03 name: Bristol-Myers Squibb class: INDUSTRY briefSummary: This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy conditions: Advanced Renal Cell Carcinoma (aRCC) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 350 type: ESTIMATED name: Nivolumab + Ipilimumab combination therapy name: Pembrolizumab + Lenvatinib combination therapy measure: Participant year of birth measure: Participant sex at birth measure: Participant primary payer measure: Participant race measure: Participant ethnicity measure: Participant U.S. state of residence measure: Participant initial Renal Cell Carcinoma (RCC) diagnoses measure: American Joint Committee on Cancer (AJCC) TNM stage measure: Participant advanced/metastatic Renal Cell Carcinoma (RCC) diagnosis measure: Participant renal cell carcinoma (RCC) histology results measure: Participant tumor grade measure: Participant biomarker or genetic testing method measure: Participant molecular and/or genetic mutations reported measure: Participant site of metastatic disease measure: Participant Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) measure: Participant Karnofsky score (KPS) measure: Participant comorbidities and/or chronic conditions measure: Participant blood test results measure: Participant Memorial Sloan Kettering Cancer Center (MSKCC) score measure: Participant International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) score measure: Participant smoking status measure: Participant COVID-19 status measure: Participant surgical history measure: Participant radiation treatment history measure: Participant treatment regimen received measure: Participant treatment initiation and discontinuation dates measure: Participant rationale for discontinuation of treatment measure: Participant radiation therapy prescribed measure: Participant total number of radiotherapy cycles measure: Participant initial dose and frequency/schedule of index therapy measure: Participant index treatment dose modifications measure: Participant rationale for dose modifications of index therapy measure: Participant date of dose modifications of index therapy measure: Participant last dose and frequency/schedule of index therapy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cardinal Health status: RECRUITING city: Dublin state: Ohio zip: 43017 country: United States lat: 40.09923 lon: -83.11408 hasResults: False
nctId: NCT06345157 id: COMB157GIT02 briefTitle: ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2026-04-30 date: 2026-04-30 date: 2024-04-03 date: 2024-04-03 name: Novartis Pharmaceuticals class: INDUSTRY briefSummary: Study to evaluate the effectiveness of ofatumumab in Italian RRMS patients in the real-life setting. conditions: Multiple Sclerosis, Relapsing-Remitting studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: Ofatumumab measure: Annualized relapse rate (ARR) measure: Proportion of patients with an improvement in SDMT (Symbol Digit Modality Test) measure: Fatigue Severity Scale [FSS] measure: Quality of life parameters assessed by EQ-5D-3L measure: Treatment satisfaction assessed by TSQM-9 measure: Expanded Disability Status Scale (EDSS) measure: Variation of NfL in plasma measure: Adverse Events (AEs) measure: Discontinuation rates due to AE and/or other reasons sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06345144 id: 202307211RINC briefTitle: Learning Experience of Undergraduate Nursing Students in Pediatric Oncology Ward overallStatus: RECRUITING date: 2023-08-22 date: 2024-03-29 date: 2024-03-29 date: 2024-04-03 date: 2024-04-03 name: National Taiwan University Hospital class: OTHER briefSummary: Clinical practices are crucial experiences for nursing students as they prepare themselves for future nursing work. Despite some research having been studied among Taiwanese nursing students in the past, there has been limited research into the experiences within pediatric oncology wards, where diseases are complex and frequently involve life-and-death issues. Therefore, the purpose of this study is to explore the experiences of undergraduate nursing students in pediatric oncology wards. conditions: Pediatric Cancer studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: RETROSPECTIVE count: 15 type: ESTIMATED measure: Explore the experiences of undergraduate nursing students practicing in pediatric oncology wards. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wei-En Li status: RECRUITING city: New Taipei City country: Taiwan name: Wei-En Li role: CONTACT lat: 25.01111 lon: 121.44583 hasResults: False
nctId: NCT06345131 id: KY20230829-06 briefTitle: Clinical Research Plan for the Safety and Accuracy of Ultrasound-guided Radial Artery Puncture Catheterization overallStatus: RECRUITING date: 2023-07-01 date: 2024-08 date: 2024-09 date: 2024-04-03 date: 2024-04-03 name: Nanjing First Hospital, Nanjing Medical University class: OTHER briefSummary: By observing the anatomical relationship and influencing factors of the radial artery through ultrasound, the optimal puncture location is selected, and puncture catheterization is guided to reduce the number of punctures, reduce complications, and improve safety and accuracy. conditions: Surgical Patients studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 100 type: ESTIMATED name: Non invasive blood pressure monitoring measure: Measure the transverse diameter of the radial artery at each anatomical point sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanjing First Hospital status: RECRUITING city: Nanjing state: Jiangsu zip: 210006 country: China name: Liu Han, MD role: CONTACT phone: 18951670163 email: han_cold.student@sina.com lat: 32.06167 lon: 118.77778 typeAbbrev: Prot_ICF hasProtocol: True hasSap: False hasIcf: True label: Study Protocol and Informed Consent Form date: 2023-07-22 uploadDate: 2024-02-14T20:25 filename: Prot_ICF_000.pdf size: 166411 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2023-07-22 uploadDate: 2024-03-05T21:35 filename: SAP_001.pdf size: 300501 hasResults: False
nctId: NCT06345118 id: FallpreventT2DMelderly briefTitle: Evaluate the Results of Fall Prevention in Older Adults With Type 2 Diabetes Mellitus acronym: FallT2DMOLD overallStatus: RECRUITING date: 2024-03-01 date: 2024-09-01 date: 2025-12-31 date: 2024-04-03 date: 2024-04-03 name: National Geriatric Hospital class: OTHER_GOV briefSummary: .This randomized controlled clinical trial aims to evaluate the effects of fall prevention in older adults with type 2 diabetes mellitus. The main questions it aims to answer are:
At the end of the intervention, the study will mainly compare the rate of fall incidents after 6 months of intervention as well as other physical performance tests. conditions: Diabetes Mellitus, Type 2 conditions: Fall conditions: Elderly Patient studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Otago exercise program measure: Physical performance 1 - Timed Up and Go (TUG) measure: Physical performance 2 -Berg Balance Scale (BBS) measure: Activities of Daily Living (ADLs) measure: Health-related Quality of Life measure: Functional Reach Test (FRT) measure: Instrumental Activities of Daily Living (IADLs) sex: ALL minimumAge: 60 Years maximumAge: 60 Years stdAges: ADULT facility: National Geriatric Hospital status: RECRUITING city: Hanoi zip: 100000 country: Vietnam name: Huyen TT Vu, PhD role: CONTACT phone: +84913531579 email: vuthanhhuyen11@yahoo.com lat: 21.0245 lon: 105.84117 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-10-11 uploadDate: 2024-03-13T14:07 filename: ICF_000.pdf size: 320767 hasResults: False
nctId: NCT06345105 id: AIeffectiveV4 briefTitle: Real Time Effective Withdrawal Time and Adenoma Detection Rate overallStatus: RECRUITING date: 2024-04-01 date: 2024-11-30 date: 2025-01-31 date: 2024-04-03 date: 2024-04-16 name: The University of Hong Kong class: OTHER briefSummary: The goal of this observational study is to assess the correlation between the artificial intelligence (AI) derived effective withdrawal time (EWT) during colonoscopy and endoscopists' baseline adenoma detection rate (ADR). The association between the AI derived EWT with ADR during the prospective colonoscopy series would also be determined. The colonoscopy video of participants will be monitored by the AI conditions: Colon Polyp conditions: Colon Adenoma conditions: Artificial Intelligence studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 198 type: ESTIMATED name: Endoscreener QC measure: Adenoma detection rates of the endoscopists measure: Adenoma detection rate measure: Polyp detection rate sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Queen Mary Hospital, the University of Hong Kong status: RECRUITING city: Hong Kong country: Hong Kong name: Thomas Ka Luen Lui role: CONTACT phone: +852 97360997 email: tkllui@hku.hk lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06345092 id: Omfs.3-3-3 briefTitle: Comparison Between IPRF With Vit. C and IPRF Alone in Management of ID'Pain overallStatus: COMPLETED date: 2022-09-01 date: 2023-03-01 date: 2023-09-01 date: 2024-04-03 date: 2024-04-04 name: Cairo University class: OTHER briefSummary: Randomized clinical trial between 2groups,the study group to be injected in the TMJ with injectable platelet rich fibrin with vitamin C and the control group to be injected in the TMJ with injectable platelet rich fibrin alone in management of internal Temporomandibular joint derangement conditions: TMJ Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 40 type: ACTUAL name: Vitamin C name: Injectable platelet rich fibrin measure: Pain management measure: disc position using MRI measure: maximum mouth opening measure: lateral excursion sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Faculty of Dentistry cairo university city: Cairo zip: +2 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06345079 id: AG0219NET briefTitle: Cessation of Somatostatin Analogues After PRRT in Mid-Gut Neuroendocrine Tumours acronym: STOPNET overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-09 date: 2028-06 date: 2024-04-03 date: 2024-04-03 name: Australasian Gastro-Intestinal Trials Group class: NETWORK name: Canadian Cancer Trials Group briefSummary: Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.
The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid and hind-gut neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA. conditions: Neuroendocrine Tumors studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 52 type: ESTIMATED name: Cessation of somatostatin analogues name: Continuation of somatostatin analogues measure: 20-month progression free survival rate after PRRT measure: Assess the barriers which would impede the feasibility of a subsequent phase 3 trial measure: Measure Quality of life using the European Organisation For Research And Treatment Of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) scales measure: Measure Quality of life using the EORTC QLQ-GINET21 scales measure: Cost-effectiveness of SSA therapy cessation measure: Psycho-oncological impacts of SSA therapy cessation: Decision Regret measure: Psycho-oncological impacts of SSA therapy cessation: Fear of Cancer Progression measure: Psycho-oncological impacts of SSA therapy cessation: Decisional Conflict measure: Time to commencement of subsequent therapy measure: Overall survival measure: Rates of SSA being recommenced over time measure: Exploratory analyses sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Royal Brisbane Women's Hospital city: Brisbane state: Queensland zip: 4006 country: Australia name: Matthew Burge role: CONTACT phone: (07) 3636 8111 email: Matthew.Burge@health.qld.gov.au name: Matthew Burge role: PRINCIPAL_INVESTIGATOR lat: -27.46794 lon: 153.02809 hasResults: False
nctId: NCT06345066 id: 18834 id: J3R-MC-YDAC type: OTHER domain: Eli Lilly And Company briefTitle: A Study of LY3841136 in Overweight and Obese Participants overallStatus: RECRUITING date: 2024-04-03 date: 2025-03 date: 2025-03 date: 2024-04-03 date: 2024-04-19 name: Eli Lilly and Company class: INDUSTRY briefSummary: The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks. conditions: Obesity conditions: Overweight studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 80 type: ESTIMATED name: Tirzepatide name: LY3841136 name: Placebo measure: Number of Participants With One or More Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration measure: Percent Change from Baseline in Body Weight measure: Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY3841136 measure: Pharmacokinetics (PK): Maximum plasma concentration (Cmax) of LY3841136 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fortrea CRU, Inc. status: RECRUITING city: Daytona Beach state: Florida zip: 32117 country: United States name: Hugh Coleman role: PRINCIPAL_INVESTIGATOR lat: 29.21081 lon: -81.02283 facility: Fortrea CRU, Inc. status: RECRUITING city: Dallas state: Texas zip: 75247 country: United States name: Archie Bowie role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 facility: Fortrea CRU, Inc. status: RECRUITING city: Madison state: Wisconsin zip: 53704 country: United States name: Nicholas Siebers role: PRINCIPAL_INVESTIGATOR lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06345053 id: 203428 briefTitle: Presence of PTSD and Emotion Dysregulation Among Inpatients With Substance Use Disorder overallStatus: RECRUITING date: 2021-05-01 date: 2024-10-01 date: 2025-10-01 date: 2024-04-03 date: 2024-04-03 name: Norwegian University of Science and Technology class: OTHER name: Møre og Romsdal Hospital Trust name: Oslo University Hospital briefSummary: There are high rates of co-occurring posttraumatic stress disorder (PTSD) among patients receiving treatment for substance use disorder (SUD). PTSD and SUD should be treated simultaneously, but adults in SUD treatment are often not assessed for PTSD nor offered PTSD-based interventions. One of the reasons for reluctance in offering trauma focused treatment is increased risk of drop out. PTSD and related emotion dysregulation are related to elevated psychological burden, higher dropout rates and increased risk of relapse. this is a feasibility study, where the plan is to integrate a combination of Dialectical Behaviour Therapy for Substance Use Disorder (DBT-SUD skills) a therapy targeting difficulties in emotion regulation and Narrative Exposure Therapy (NET) a trauma focused therapy, for patients with co-occurring PTSD symptoms into standard SUD treatment . The plan is to assess its potential benefits by assessing whether adding this combination to standard SUD treatment is relevant, feasible, acceptable, and safe. Treatment outcomes are 1) Prevalence of PTSD, suicidal behaviour, and self-harm, as well as the severity of difficulties in emotion regulation and emotional avoidance among patients (N approx. = 100) in inpatient treatment for SUD. 2) Change post-treatment and at 3 and 12 months follow up, from baseline in PTSD symptom severity, depressive symptoms, emotion regulation, emotion avoidance, and experience of shame. 3) Rates of dropout and relapse compared to previous rates.
This project can increase knowledge about psychological mechanisms in co-occurring PTSD and SUD and improve the quality of treatment for this vulnerable patient population. conditions: Post Traumatic Stress Disorder conditions: Substance Use Disorders conditions: Emotion Regulation conditions: Suicide conditions: Self-harm studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a repeated measures follow-up feasibility study without control group. primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Narrative Exposure Therapy measure: The intervention is relevant - prevalence of PTSD /SUP PTSD. measure: The intervention is relevant - prevalence of traumatic experiences. measure: The intervention is relevant - The severitiy of difficulties in emotion regulation. measure: The intervention is feasible, accepted and safe - The dropout rate from treatment. measure: The intervention is safe - Suicide behaviour while in treatment. measure: The intervention is safe - Self-harm behaviour while in treatment. measure: The intervention is accepted - participation in DBT-SUD skills sessions. measure: The intervention is feasible and accepted - Objective experience of treatment. measure: The potential benefits of the intervention - Change in PTSD symptoms from base line to 3-and 12 month follow up. measure: The potential benefits of the intervention - Change in Difficulties in emotion regulation from baseline to 3- to 12- month follow up. measure: The potential benefits of the intervention - Relapse to alcohol abuse at 3- and 12-months follow up. measure: The potential benefits of the intervention - Relapse to substance abuse at 3- and 12-month follow up. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Molde Treatment Center, Møre and Romsdal Hospital Trust status: RECRUITING city: Molde state: Møre And Romsdal zip: 6410 country: Norway name: Edvard Breivik role: CONTACT phone: +4793032613 email: edvard.breivik@helse-mr.no name: Johanna Vigfusdottir role: CONTACT phone: +4746746154 email: johannavigfusd@gmail.com lat: 62.73752 lon: 7.15912 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2024-03-15 uploadDate: 2024-03-18T06:41 filename: Prot_SAP_000.pdf size: 766255 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-03-25 uploadDate: 2024-03-25T10:01 filename: ICF_001.pdf size: 621574 hasResults: False
nctId: NCT06345027 id: H-53163 CASEY briefTitle: CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) acronym: CASEY overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-05-01 date: 2042-04-01 date: 2024-04-03 date: 2024-04-03 name: Baylor College of Medicine class: OTHER briefSummary: This study is for patients that have lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease and the patients condition has come back or has not gone away after treatment, including the best treatment we know for these diseases.
Some patients with Lymphoma or T/NK-lymphoproliferative disease show signs of virus that is sometimes called Epstein Barr virus (EBV). This virus causes mononucleosis or glandular fever ("mono") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with Hodgkin's and non-Hodgkin Lymphoma. This suggests that the EBV plays a role in causing Lymphoma. The cancer cells (in lymphoma) and some immune system cells infected by EBV are able to hide from the body's immune system and escape destruction.
T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. T cells have been used to treat patients with cancers. T cells, that have been trained to kill EBV infected cells can survive in blood and affect the tumor. We have treated over 80 people on studies using T cells to target these diseases. About half of those patients who had disease at the time they got the cells had responses including some patients with complete responses (meaning the cancer could no longer be detected).
We think that if T cells are able to last longer in the body, they may have a better chance of killing EBV and EBV infected tumor cells. Therefore, in this study we will add a new gene to the EBV T cells that can cause the cells to live longer called C7R. We know that T cells need substances called cytokines (substances such as proteins released by specific cells of the immune system) to survive and that the cells may not get enough cytokines after the cells are infused into the body. We have added the gene C7R that gives the cells a constant supply of cytokine and helps them to survive for a longer period of time.
The purpose of this study is to find the largest safe dose of C7R-EBV T cells, and additionally to evaluate how long they can be detected in the blood and what affect they have on the cancer. conditions: Leukemia, Myeloid, Acute conditions: Leukemia, B-cell conditions: Leukemia, T-Cell conditions: Lymphoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Treatment Arm A measure: Dose limiting toxicity (DLT) rate measure: Overall Response Rate sex: ALL maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Texas Children's Hospital city: Houston state: Texas zip: 77030 country: United States name: Bilal Omer, MD role: CONTACT phone: 832-826-0860 email: baomer@texaschildrens.org lat: 29.76328 lon: -95.36327 facility: The Methodist Hospital city: Houston state: Texas zip: 77030 country: United States name: Bilal Omer, MD role: CONTACT phone: 832-826-0860 email: baomer@texaschildrens.org lat: 29.76328 lon: -95.36327 hasResults: False